HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
Asia Biotech Live
LATEST UPDATES » Vol 24, No 01, January 2020 – Empowering the Patient - Personalization of Diabetes Management       » First of its kind Human Heart-in-a-Jar Model for therapeutic solutions       » China's National Vaccine Tracking System set to be completed in 2020       » China's amended drug administration law kicks in       » Human activity puts Chinese plant biodiversity at risk, study finds       » Contributory effects of each brain cell type in development of Alzheimer's Disease      
Vol 23, No. 11, November 2019For e-subscribers (PDF)
EYE ON CHINA
Discovery of cancer-causing gene reveals new anti-cancer therapy potential
Study published online in PNAS, describes a novel druggable oncogenic driver gene in human gastrointestinal stromal tumours (GISTs).

The research team led by Professor Wang Yuexiang of the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences, together with Professor Jonathan Fletcher from Brigham Women鈥檚 Hospital and Harvard Medical School used whole exome sequencing and reported recurrent genomic inactivated DEPDC5 gene mutations in GIST. DEPDC5 was shown to be a chromosome 22q-targeting tumour suppressor, silenced by mutations in GIST specifically.

Chromosome 22q deletions are frequent chromosomal abnormalities in human GISTs, occurring in approximately 50 percent of GISTs, and are thought to contribute to the pathogenesis of this disease. This research uncovers the crucial gene in chromosome 22q that is related to the genomic alterations.

The evidence showed that inactivation of DEPDC5 promotes rapid increase in GIST cells by activating the mTORC1 signalling pathway and subsequently preventing cell cycle arrest. They demonstrated that DEPDC5 modulates the sensitivity of GIST to KIT inhibitors, and combination therapy using the mTOR inhibitor and KIT inhibitor may work better in GIST patients with DEPDC5 inhibition.

Recurrent genomic alterations and functional data validate DEPDC5 as a tumour suppressor contributing to GIST progression and biologically relevant target of frequent chromosome 22q deletions. The DEPDC5-inactivated mutation will be able to serve as a predictive course of GIST as they are associated with aggressive GISTs, where they promote GIST progression and reduce sensitivity to KIT indicators.

The inactivation of DEPDC5 gene has also been found to be associated with the disease mechanism of focal epilepsy. Thus, highlighting that recent therapeutic developments for focal epilepsy could also serve as anti-cancer drugs.

Click here for the complete issue.

NEWS CRUNCH  
news Joining Forces to Elevate Asia's Healthcare Industry
news 4th Global Feed Summit draws Feed Producers, Technology Providers, Raw Materials Suppliers to Bangkok for Key Discussions
news 2nd China Pharma Digital Innovation Summit to be held in Shanghai
news 2nd China Healthcare Digital Innovation Summit to be held in Shanghai
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy